Industry
Court Ruling Could Invalidate Numerous Genome Patents
August 2008 | Industry NewsA UK court decision invalidating a patent for a nucleotide and amino acid sequence of the human genome looks set to raise the bar for protecting intellectual property (IP). In the UK's first case relating to the validity of a gene sequence, the court ruled in favour of Eli Lilly after it found that Human Genome Sciences (HGS)' patent on neutrokine-α lacked industrial application, had insufficient evidence and was
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
